DOI QR코드

DOI QR Code

Early Efficacy of Endostar Combined with Chemoradiotherapy for Advanced Cervical Cancers

  • Ke, Qing-Hua (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Zhou, Shi-Qiong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Huang, Min (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Lei, Yong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Du, Wei (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Yang, Ji-Yuan (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
  • Published : 2012.03.31

Abstract

The aim of this study was to investigate the early outcome of Endostar combined with chemoradiotherapy for advanced cervical cancer. Fifty-two cases (FIGO IIb to IVa) were divided randomly into two groups, receiving chemoradiotherapy alone (CRT group) and Endostar combined with chemoradiotherapy (CRT+E group). For the patients in the CRT+E group, Endostar was administered daily with the dosage of 7.5 $mg/m^2$, and cisplatin was administered weekly with the dosage of 20 $mg/m^2$ during the radiation. The regimens lasted for 4 weeks with no difference in chemoradiotherapy between the two groups. The early outcome complete remission rate was 73.1%, partial remission rate was 23.1% and the total response rate was 96.2% in CRT+E group, a significant improvement on the 34.6%, 42.3% and 76.9%, respectively, in the CRT group. One year survive rates were 100% and 84.6% in the CRT+E group and CRT groups, the difference being significant. Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.

References

  1. Brideau G, Makinen MJ, Elamaa H, et al (2007). Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res, 67, 11528-35. https://doi.org/10.1158/0008-5472.CAN-07-1458
  2. Duenas-Gonzale A, Zarba JJ, Alcedo JC, et al (2007). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol, 29, 1678-85.
  3. Dubay RA, Rose PG, O'Malley DM, et al (2004). Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol, 94, 121-4. https://doi.org/10.1016/j.ygyno.2004.03.034
  4. Duenas-Gonzalez A, Zarba JJ, Patel F, et al (2011). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol, 29, 1678-85. https://doi.org/10.1200/JCO.2009.25.9663
  5. Eifel PJ, Winter K, Morris M, et al (2004). Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high- risk cervical cancer: an update of radiation therapy oncology group trial (RTOG). 90-01. J Clin Oncol, 22, 872-80. https://doi.org/10.1200/JCO.2004.07.197
  6. Fukumoto S, Morifuji M, Katakury Y, et al (2005). Endostatin inhibits lymph node metastasis by a down- regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis, 22, 31- 8. https://doi.org/10.1007/s10585-005-3973-5
  7. Ge W, Cao DD, Wang HM, et al (2011). Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev, 12, 2705-11.
  8. Han BH, Xiu QY, Wang HM,et al (2011). A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxelcarboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC). Zhonghua Zhong Liu Za Zhi, 33, 854-9.
  9. Han B, Xiu Q, Wang H, et al (2011). A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol, 6, 1104-9. https://doi.org/10.1097/JTO.0b013e3182166b6b
  10. Jia Y, Liu M, Cao L, et al (2011). Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol, 32, 316-24.
  11. Li Y, Huang XE, Yan PW, et al (2010). Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev, 11, 1119-23.
  12. Li N, Jin ZL, Liu ZJ, et al (2011). Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi, 33, 937-42.
  13. Lu P, Liang QD, Zheng QQ (2003). Influence of clinical and pathologic parameters on prognosis of cervical carcinoma in China. Chinese-German J Clin Oncol, 2, 163-5.
  14. Sun Y, Shi YK (2007). 5 Edition. Beijing: People's Medical Publishing House. Manual Med Oncol, 142-624.
  15. Peters WA, Liu PY, Barrett RJ, et al (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high -risk early-stage cancer of the cervical. J Clin Oncol, 18, 1606-13. https://doi.org/10.1200/JCO.2000.18.8.1606
  16. Rose PG, Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 25, 2804-10. https://doi.org/10.1200/JCO.2006.09.4532
  17. Rose PG, Bundy BN, Watkins EB, et al (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med, 340, 1144-53. https://doi.org/10.1056/NEJM199904153401502
  18. Rose PG,Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy ,or hydroxyurea during pelvic irradiation for locally advanced cervical cancer:a Gynecologic Oncology Group Study. J Clin Oncol, 25, 2804-10. https://doi.org/10.1200/JCO.2006.09.4532
  19. Xin G, Du J, Zhu L, et al (2011). Differential anti-tumor effects for various regimens of endostar plus cisplatin in ovarian cancer. Zhonghua Yi Xue Za Zhi, 91, 3367-70.
  20. Luo X, Liu W (2006). Endostar. Chinese J New Drugs, 15, 1893-5.
  21. Yitao JIA , Zhongxin LI , Min LIU, et a1 (2009). Endostar reduces the growth and metastasis by inhibiting angiogenesis and lymphangiogenesis in nude mouse models of human cervical cancer. Chinese J Oncol, 31, 254-7.
  22. Zhou JF, Bai CM, Wang YZ, et al (2011). Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study. Chin Med J, 124, 4299-303.

Cited by

  1. Salvage Therapy of Gemcitabine Plus Endostar Significantly Improves Progression-free Survival (PFS) with Platinum-resistant Recurrent Epithelial Ovarian Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1841
  2. Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4255
  3. Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer vol.4, pp.4, 2013, https://doi.org/10.1111/1759-7714.12050
  4. Critical Role of Aberrant Angiogenesis in the Development of Tumor Hypoxia and Associated Radioresistance vol.6, pp.2, 2014, https://doi.org/10.3390/cancers6020813
  5. Contrast-enhanced ultrasound analysis of tissue perfusion in tumor-bearing mice following treatment with endostatin combined with radiotherapy vol.7, pp.5, 2014, https://doi.org/10.3892/etm.2014.1594
  6. APJ Is Associated with Treatment Response in Gastric Cancer Patients Receiving Concurrent Chemoradiotherapy and Endostar Therapy vol.32, pp.4, 2017, https://doi.org/10.1089/cbr.2016.2138
  7. Monitoring Tumor Targeting and Treatment Effects of IRDye 800CW and GX1-Conjugated Polylactic Acid Nanoparticles Encapsulating Endostar on Glioma by Optical Molecular Imaging vol.14, pp.7, 2015, https://doi.org/10.2310/7290.2015.00014
  8. Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma vol.13, pp.3, 2017, https://doi.org/10.3892/ol.2017.5559
  9. Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion vol.96, pp.51, 2017, https://doi.org/10.1097/MD.0000000000009077